📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Shivalik Rasayan Q3 FY26 Consolidated Net Profit Drops 47% YoY to ₹3.67 Crore
Shivalik Rasayan reported a weak performance for the quarter ended December 31, 2025, with consolidated net profit declining 47.1% YoY to ₹3.67 crore. Total consolidated revenue fell 4.2% YoY to ₹83.21 crore, also showing a sequential decline of 11.7% from the previous quarter. The Agrochemicals segment faced significant margin pressure, with segment results falling from ₹718.61 lakhs to ₹592.72 lakhs YoY. The company's consolidated performance remains heavily dependent on its Pharma Formulations segment and its associate, Medicamen Biotech Limited.
Key Highlights
Consolidated Net Profit fell 47.1% YoY to ₹366.95 Lakhs from ₹693.79 Lakhs.
Consolidated Revenue from operations decreased to ₹8,203.75 Lakhs compared to ₹8,530.61 Lakhs in Q3 FY25.
Standalone Net Profit saw a sharp decline to ₹203.49 Lakhs from ₹401.59 Lakhs in the year-ago period.
Consolidated EPS for the quarter dropped significantly to ₹1.71 from ₹3.39 YoY.
Agrochemicals segment revenue stood at ₹2,810.56 Lakhs, while Pharma Formulations contributed ₹4,690.85 Lakhs to consolidated totals.
💼 Action for Investors
Investors should exercise caution as the company is experiencing a significant contraction in both top-line and bottom-line growth. The sharp decline in EPS and segment margins suggests operational headwinds that may require a few quarters to stabilize.